NeuroStar® Safety

Clinical trials have demonstrated the safety of NeuroStar TMS Therapy® in treating patients who have had an inadequate response to prior antidepressant medications.

Treatment with NeuroStar TMS Therapy is very well tolerated by patients and causes very few side effects. More than 95% of patients completed the full course of treatment and fewer than 5% discontinued treatment due to adverse events. The most common side effect reported during clinical trials was scalp discomfort – generally mild to moderate and occurring less frequently after the first week of treatment.

Over 10,000 active treatments were performed across all Neurostar clinical trials, demonstrating both its safety and benefits to patients, including:

• No systemic side effects
  • No weight gain
  • No sexual dysfunction
  • No sedation
  • No nausea
  • No dry mouth
• No adverse effects on concentration or memory
• No drug interactions
• NeuroStar TMS Therapy should not be used in patients with implanted metallic devices or non-removable metallic objects in or around the head. This does not include metallic fillings in teeth.
• NeuroStar TMS Therapy should not be used in patients with implants controlled by physiological signals. This includes pacemakers, implantable cardioverter defibrillators (ICDs), and vagus nerve stimulators (VNS).
• Covered by most insurance plans – we assist patient with the insurance authorization and reimbursement process

Learn about a typical NeuroStar TMS Therapy treatment session.

References:

1. Janicak, P, et al. Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure and During Reintroduction Treatment. Journal of Clinical Psychiatry, February 2008.